nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—Dyspnoea—Mitomycin—urinary bladder cancer	0.0031	0.00595	CcSEcCtD
Metoclopramide—Somnolence—Mitomycin—urinary bladder cancer	0.0031	0.00594	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Cisplatin—urinary bladder cancer	0.00308	0.00591	CcSEcCtD
Metoclopramide—Nausea—Valrubicin—urinary bladder cancer	0.003	0.00576	CcSEcCtD
Metoclopramide—Fatigue—Mitomycin—urinary bladder cancer	0.003	0.00576	CcSEcCtD
Metoclopramide—Feeling abnormal—Mitomycin—urinary bladder cancer	0.00287	0.0055	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Etoposide—urinary bladder cancer	0.00282	0.00541	CcSEcCtD
Metoclopramide—Cardiac arrest—Fluorouracil—urinary bladder cancer	0.0028	0.00537	CcSEcCtD
Metoclopramide—Body temperature increased—Mitomycin—urinary bladder cancer	0.00275	0.00528	CcSEcCtD
Metoclopramide—Hepatotoxicity—Methotrexate—urinary bladder cancer	0.00274	0.00525	CcSEcCtD
Metoclopramide—Jaundice—Thiotepa—urinary bladder cancer	0.00268	0.00513	CcSEcCtD
Metoclopramide—Agranulocytosis—Thiotepa—urinary bladder cancer	0.00256	0.00491	CcSEcCtD
Metoclopramide—Bronchospasm—Gemcitabine—urinary bladder cancer	0.00255	0.00489	CcSEcCtD
Metoclopramide—Asthenia—Mitomycin—urinary bladder cancer	0.0025	0.00479	CcSEcCtD
Metoclopramide—Hallucination—Thiotepa—urinary bladder cancer	0.00245	0.0047	CcSEcCtD
Metoclopramide—Cardiac arrest—Etoposide—urinary bladder cancer	0.00243	0.00467	CcSEcCtD
Metoclopramide—Neutropenia—Gemcitabine—urinary bladder cancer	0.00242	0.00465	CcSEcCtD
Metoclopramide—Diarrhoea—Mitomycin—urinary bladder cancer	0.00238	0.00457	CcSEcCtD
Metoclopramide—Blood disorder—Epirubicin—urinary bladder cancer	0.00237	0.00454	CcSEcCtD
Metoclopramide—Dizziness—Mitomycin—urinary bladder cancer	0.0023	0.00442	CcSEcCtD
Metoclopramide—Delirium—Epirubicin—urinary bladder cancer	0.0023	0.00441	CcSEcCtD
Metoclopramide—Amenorrhoea—Epirubicin—urinary bladder cancer	0.00225	0.00431	CcSEcCtD
Metoclopramide—Rash—Mitomycin—urinary bladder cancer	0.0022	0.00421	CcSEcCtD
Metoclopramide—Dermatitis—Mitomycin—urinary bladder cancer	0.00219	0.00421	CcSEcCtD
Metoclopramide—Blood disorder—Doxorubicin—urinary bladder cancer	0.00219	0.0042	CcSEcCtD
Metoclopramide—Headache—Mitomycin—urinary bladder cancer	0.00218	0.00418	CcSEcCtD
Metoclopramide—Bronchospasm—Etoposide—urinary bladder cancer	0.00218	0.00417	CcSEcCtD
Metoclopramide—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.00216	0.00413	CcSEcCtD
Metoclopramide—Respiratory failure—Methotrexate—urinary bladder cancer	0.00215	0.00412	CcSEcCtD
Metoclopramide—Delirium—Doxorubicin—urinary bladder cancer	0.00213	0.00408	CcSEcCtD
Metoclopramide—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.00212	0.00406	CcSEcCtD
Metoclopramide—Dyskinesia—Epirubicin—urinary bladder cancer	0.0021	0.00403	CcSEcCtD
Metoclopramide—Nervousness—Thiotepa—urinary bladder cancer	0.00208	0.004	CcSEcCtD
Metoclopramide—Amenorrhoea—Doxorubicin—urinary bladder cancer	0.00208	0.00399	CcSEcCtD
Metoclopramide—Neutropenia—Etoposide—urinary bladder cancer	0.00207	0.00397	CcSEcCtD
Metoclopramide—Nausea—Mitomycin—urinary bladder cancer	0.00207	0.00397	CcSEcCtD
Metoclopramide—Atrioventricular block—Epirubicin—urinary bladder cancer	0.00204	0.00391	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Epirubicin—urinary bladder cancer	0.00198	0.00379	CcSEcCtD
Metoclopramide—Agitation—Thiotepa—urinary bladder cancer	0.00197	0.00378	CcSEcCtD
Metoclopramide—Bradycardia—Cisplatin—urinary bladder cancer	0.00197	0.00377	CcSEcCtD
Metoclopramide—Dyskinesia—Doxorubicin—urinary bladder cancer	0.00195	0.00373	CcSEcCtD
Metoclopramide—Jaundice—Etoposide—urinary bladder cancer	0.00192	0.00369	CcSEcCtD
Metoclopramide—Leukopenia—Thiotepa—urinary bladder cancer	0.00192	0.00368	CcSEcCtD
Metoclopramide—Gynaecomastia—Methotrexate—urinary bladder cancer	0.00189	0.00362	CcSEcCtD
Metoclopramide—Atrioventricular block—Doxorubicin—urinary bladder cancer	0.00189	0.00362	CcSEcCtD
Metoclopramide—Fluid retention—Epirubicin—urinary bladder cancer	0.00188	0.0036	CcSEcCtD
Metoclopramide—Visual impairment—Cisplatin—urinary bladder cancer	0.00186	0.00357	CcSEcCtD
Metoclopramide—Convulsion—Thiotepa—urinary bladder cancer	0.00186	0.00357	CcSEcCtD
Metoclopramide—Hypertension—Thiotepa—urinary bladder cancer	0.00185	0.00355	CcSEcCtD
Metoclopramide—Agranulocytosis—Etoposide—urinary bladder cancer	0.00184	0.00353	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Doxorubicin—urinary bladder cancer	0.00183	0.00351	CcSEcCtD
Metoclopramide—Anxiety—Thiotepa—urinary bladder cancer	0.00182	0.00349	CcSEcCtD
Metoclopramide—Rash maculo-papular—Epirubicin—urinary bladder cancer	0.0018	0.00345	CcSEcCtD
Metoclopramide—Flushing—Cisplatin—urinary bladder cancer	0.00179	0.00344	CcSEcCtD
Metoclopramide—Confusional state—Thiotepa—urinary bladder cancer	0.00177	0.00339	CcSEcCtD
Metoclopramide—Fluid retention—Doxorubicin—urinary bladder cancer	0.00174	0.00333	CcSEcCtD
Metoclopramide—Tachycardia—Thiotepa—urinary bladder cancer	0.00171	0.00328	CcSEcCtD
Metoclopramide—Rash maculo-papular—Doxorubicin—urinary bladder cancer	0.00166	0.00319	CcSEcCtD
Metoclopramide—Flushing—Etoposide—urinary bladder cancer	0.00164	0.00315	CcSEcCtD
Metoclopramide—Visual disturbance—Methotrexate—urinary bladder cancer	0.00162	0.0031	CcSEcCtD
Metoclopramide—Muscle spasms—Cisplatin—urinary bladder cancer	0.00162	0.0031	CcSEcCtD
Metoclopramide—Leukopenia—Gemcitabine—urinary bladder cancer	0.00162	0.0031	CcSEcCtD
Metoclopramide—Leukopenia—Fluorouracil—urinary bladder cancer	0.00159	0.00305	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Epirubicin—urinary bladder cancer	0.00158	0.00303	CcSEcCtD
Metoclopramide—Tremor—Cisplatin—urinary bladder cancer	0.00158	0.00302	CcSEcCtD
Metoclopramide—Hypertension—Gemcitabine—urinary bladder cancer	0.00156	0.00299	CcSEcCtD
Metoclopramide—Somnolence—Thiotepa—urinary bladder cancer	0.00156	0.00299	CcSEcCtD
Metoclopramide—Convulsion—Fluorouracil—urinary bladder cancer	0.00154	0.00295	CcSEcCtD
Metoclopramide—Fatigue—Thiotepa—urinary bladder cancer	0.00151	0.0029	CcSEcCtD
Metoclopramide—Renal impairment—Epirubicin—urinary bladder cancer	0.00151	0.00289	CcSEcCtD
Metoclopramide—Leukopenia—Cisplatin—urinary bladder cancer	0.00151	0.00289	CcSEcCtD
Metoclopramide—Muscle spasms—Etoposide—urinary bladder cancer	0.00148	0.00284	CcSEcCtD
Metoclopramide—Oedema—Gemcitabine—urinary bladder cancer	0.00147	0.00283	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Doxorubicin—urinary bladder cancer	0.00146	0.00281	CcSEcCtD
Metoclopramide—Confusional state—Fluorouracil—urinary bladder cancer	0.00146	0.0028	CcSEcCtD
Metoclopramide—Convulsion—Cisplatin—urinary bladder cancer	0.00146	0.0028	CcSEcCtD
Metoclopramide—Oedema—Fluorouracil—urinary bladder cancer	0.00145	0.00278	CcSEcCtD
Metoclopramide—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00144	0.00277	CcSEcCtD
Metoclopramide—Anxiety—Cisplatin—urinary bladder cancer	0.00143	0.00274	CcSEcCtD
Metoclopramide—Tachycardia—Fluorouracil—urinary bladder cancer	0.00141	0.00271	CcSEcCtD
Metoclopramide—Renal impairment—Doxorubicin—urinary bladder cancer	0.00139	0.00268	CcSEcCtD
Metoclopramide—Urticaria—Thiotepa—urinary bladder cancer	0.00139	0.00267	CcSEcCtD
Metoclopramide—Body temperature increased—Thiotepa—urinary bladder cancer	0.00138	0.00266	CcSEcCtD
Metoclopramide—Leukopenia—Etoposide—urinary bladder cancer	0.00138	0.00265	CcSEcCtD
Metoclopramide—Hypotension—Gemcitabine—urinary bladder cancer	0.00138	0.00264	CcSEcCtD
Metoclopramide—Oedema—Cisplatin—urinary bladder cancer	0.00137	0.00263	CcSEcCtD
Metoclopramide—Cardiac arrest—Epirubicin—urinary bladder cancer	0.00136	0.00262	CcSEcCtD
Metoclopramide—Hypotension—Fluorouracil—urinary bladder cancer	0.00135	0.0026	CcSEcCtD
Metoclopramide—Tachycardia—Cisplatin—urinary bladder cancer	0.00134	0.00257	CcSEcCtD
Metoclopramide—Convulsion—Etoposide—urinary bladder cancer	0.00134	0.00256	CcSEcCtD
Metoclopramide—Insomnia—Gemcitabine—urinary bladder cancer	0.00133	0.00256	CcSEcCtD
Metoclopramide—Hypertension—Etoposide—urinary bladder cancer	0.00133	0.00255	CcSEcCtD
Metoclopramide—Asthma—Methotrexate—urinary bladder cancer	0.00133	0.00254	CcSEcCtD
Metoclopramide—Dyspnoea—Gemcitabine—urinary bladder cancer	0.00131	0.00252	CcSEcCtD
Metoclopramide—Insomnia—Fluorouracil—urinary bladder cancer	0.00131	0.00251	CcSEcCtD
Metoclopramide—Somnolence—Gemcitabine—urinary bladder cancer	0.00131	0.00251	CcSEcCtD
Metoclopramide—Dyspnoea—Fluorouracil—urinary bladder cancer	0.00129	0.00248	CcSEcCtD
Metoclopramide—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00129	0.00247	CcSEcCtD
Metoclopramide—Somnolence—Fluorouracil—urinary bladder cancer	0.00129	0.00247	CcSEcCtD
Metoclopramide—Hypotension—Cisplatin—urinary bladder cancer	0.00128	0.00246	CcSEcCtD
Metoclopramide—Fatigue—Gemcitabine—urinary bladder cancer	0.00127	0.00244	CcSEcCtD
Metoclopramide—Confusional state—Etoposide—urinary bladder cancer	0.00127	0.00243	CcSEcCtD
Metoclopramide—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.00126	0.00242	CcSEcCtD
Metoclopramide—Asthenia—Thiotepa—urinary bladder cancer	0.00126	0.00241	CcSEcCtD
Metoclopramide—Asthma—Epirubicin—urinary bladder cancer	0.00124	0.00238	CcSEcCtD
Metoclopramide—Neutropenia—Methotrexate—urinary bladder cancer	0.00124	0.00238	CcSEcCtD
Metoclopramide—Tachycardia—Etoposide—urinary bladder cancer	0.00123	0.00235	CcSEcCtD
Metoclopramide—Dyspnoea—Cisplatin—urinary bladder cancer	0.00122	0.00235	CcSEcCtD
Metoclopramide—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00122	0.00234	CcSEcCtD
Metoclopramide—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00121	0.00233	CcSEcCtD
Metoclopramide—Diarrhoea—Thiotepa—urinary bladder cancer	0.0012	0.0023	CcSEcCtD
Metoclopramide—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00119	0.00229	CcSEcCtD
Metoclopramide—Drowsiness—Methotrexate—urinary bladder cancer	0.00118	0.00227	CcSEcCtD
Metoclopramide—Depression—Methotrexate—urinary bladder cancer	0.00118	0.00226	CcSEcCtD
Metoclopramide—Hypotension—Etoposide—urinary bladder cancer	0.00118	0.00225	CcSEcCtD
Metoclopramide—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00116	0.00223	CcSEcCtD
Metoclopramide—Neutropenia—Epirubicin—urinary bladder cancer	0.00116	0.00222	CcSEcCtD
Metoclopramide—Dizziness—Thiotepa—urinary bladder cancer	0.00116	0.00222	CcSEcCtD
Metoclopramide—Urticaria—Fluorouracil—urinary bladder cancer	0.00115	0.00221	CcSEcCtD
Metoclopramide—Asthma—Doxorubicin—urinary bladder cancer	0.00115	0.0022	CcSEcCtD
Metoclopramide—Pollakiuria—Epirubicin—urinary bladder cancer	0.00115	0.0022	CcSEcCtD
Metoclopramide—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00115	0.0022	CcSEcCtD
Metoclopramide—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00113	0.00217	CcSEcCtD
Metoclopramide—Dyspnoea—Etoposide—urinary bladder cancer	0.00112	0.00215	CcSEcCtD
Metoclopramide—Somnolence—Etoposide—urinary bladder cancer	0.00112	0.00214	CcSEcCtD
Metoclopramide—Drowsiness—Epirubicin—urinary bladder cancer	0.00111	0.00212	CcSEcCtD
Metoclopramide—Rash—Thiotepa—urinary bladder cancer	0.0011	0.00212	CcSEcCtD
Metoclopramide—Dermatitis—Thiotepa—urinary bladder cancer	0.0011	0.00212	CcSEcCtD
Metoclopramide—Agranulocytosis—Methotrexate—urinary bladder cancer	0.0011	0.00211	CcSEcCtD
Metoclopramide—Headache—Thiotepa—urinary bladder cancer	0.0011	0.0021	CcSEcCtD
Metoclopramide—Body temperature increased—Cisplatin—urinary bladder cancer	0.00109	0.00208	CcSEcCtD
Metoclopramide—Fatigue—Etoposide—urinary bladder cancer	0.00108	0.00208	CcSEcCtD
Metoclopramide—Jaundice—Epirubicin—urinary bladder cancer	0.00108	0.00207	CcSEcCtD
Metoclopramide—Neutropenia—Doxorubicin—urinary bladder cancer	0.00107	0.00206	CcSEcCtD
Metoclopramide—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00107	0.00205	CcSEcCtD
Metoclopramide—Pollakiuria—Doxorubicin—urinary bladder cancer	0.00106	0.00203	CcSEcCtD
Metoclopramide—Asthenia—Gemcitabine—urinary bladder cancer	0.00106	0.00203	CcSEcCtD
Metoclopramide—Nausea—Thiotepa—urinary bladder cancer	0.00104	0.00199	CcSEcCtD
Metoclopramide—Feeling abnormal—Etoposide—urinary bladder cancer	0.00104	0.00199	CcSEcCtD
Metoclopramide—Agranulocytosis—Epirubicin—urinary bladder cancer	0.00103	0.00198	CcSEcCtD
Metoclopramide—Drowsiness—Doxorubicin—urinary bladder cancer	0.00102	0.00196	CcSEcCtD
Metoclopramide—Visual impairment—Methotrexate—urinary bladder cancer	0.00102	0.00196	CcSEcCtD
Metoclopramide—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00101	0.00194	CcSEcCtD
Metoclopramide—Bradycardia—Epirubicin—urinary bladder cancer	0.00101	0.00194	CcSEcCtD
Metoclopramide—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00101	0.00193	CcSEcCtD
Metoclopramide—Urticaria—Etoposide—urinary bladder cancer	0.000999	0.00192	CcSEcCtD
Metoclopramide—Jaundice—Doxorubicin—urinary bladder cancer	0.000997	0.00191	CcSEcCtD
Metoclopramide—Body temperature increased—Etoposide—urinary bladder cancer	0.000994	0.00191	CcSEcCtD
Metoclopramide—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000991	0.0019	CcSEcCtD
Metoclopramide—Asthenia—Cisplatin—urinary bladder cancer	0.000985	0.00189	CcSEcCtD
Metoclopramide—Dizziness—Fluorouracil—urinary bladder cancer	0.000958	0.00184	CcSEcCtD
Metoclopramide—Visual impairment—Epirubicin—urinary bladder cancer	0.000957	0.00183	CcSEcCtD
Metoclopramide—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000955	0.00183	CcSEcCtD
Metoclopramide—Diarrhoea—Cisplatin—urinary bladder cancer	0.00094	0.0018	CcSEcCtD
Metoclopramide—Bradycardia—Doxorubicin—urinary bladder cancer	0.000935	0.00179	CcSEcCtD
Metoclopramide—Rash—Gemcitabine—urinary bladder cancer	0.000929	0.00178	CcSEcCtD
Metoclopramide—Dermatitis—Gemcitabine—urinary bladder cancer	0.000928	0.00178	CcSEcCtD
Metoclopramide—Hypersensitivity—Etoposide—urinary bladder cancer	0.000927	0.00178	CcSEcCtD
Metoclopramide—Headache—Gemcitabine—urinary bladder cancer	0.000923	0.00177	CcSEcCtD
Metoclopramide—Flushing—Epirubicin—urinary bladder cancer	0.000921	0.00177	CcSEcCtD
Metoclopramide—Rash—Fluorouracil—urinary bladder cancer	0.000913	0.00175	CcSEcCtD
Metoclopramide—Dermatitis—Fluorouracil—urinary bladder cancer	0.000912	0.00175	CcSEcCtD
Metoclopramide—Headache—Fluorouracil—urinary bladder cancer	0.000907	0.00174	CcSEcCtD
Metoclopramide—Asthenia—Etoposide—urinary bladder cancer	0.000903	0.00173	CcSEcCtD
Metoclopramide—Visual impairment—Doxorubicin—urinary bladder cancer	0.000885	0.0017	CcSEcCtD
Metoclopramide—Nausea—Gemcitabine—urinary bladder cancer	0.000875	0.00168	CcSEcCtD
Metoclopramide—Rash—Cisplatin—urinary bladder cancer	0.000866	0.00166	CcSEcCtD
Metoclopramide—Dermatitis—Cisplatin—urinary bladder cancer	0.000865	0.00166	CcSEcCtD
Metoclopramide—Diarrhoea—Etoposide—urinary bladder cancer	0.000861	0.00165	CcSEcCtD
Metoclopramide—Nausea—Fluorouracil—urinary bladder cancer	0.00086	0.00165	CcSEcCtD
Metoclopramide—Flushing—Doxorubicin—urinary bladder cancer	0.000852	0.00163	CcSEcCtD
Metoclopramide—Nervousness—Epirubicin—urinary bladder cancer	0.000839	0.00161	CcSEcCtD
Metoclopramide—Dizziness—Etoposide—urinary bladder cancer	0.000832	0.0016	CcSEcCtD
Metoclopramide—Muscle spasms—Epirubicin—urinary bladder cancer	0.000831	0.00159	CcSEcCtD
Metoclopramide—Leukopenia—Methotrexate—urinary bladder cancer	0.000826	0.00158	CcSEcCtD
Metoclopramide—Nausea—Cisplatin—urinary bladder cancer	0.000816	0.00156	CcSEcCtD
Metoclopramide—Convulsion—Methotrexate—urinary bladder cancer	0.0008	0.00153	CcSEcCtD
Metoclopramide—Agitation—Epirubicin—urinary bladder cancer	0.000794	0.00152	CcSEcCtD
Metoclopramide—Rash—Etoposide—urinary bladder cancer	0.000793	0.00152	CcSEcCtD
Metoclopramide—Dermatitis—Etoposide—urinary bladder cancer	0.000792	0.00152	CcSEcCtD
Metoclopramide—Headache—Etoposide—urinary bladder cancer	0.000788	0.00151	CcSEcCtD
Metoclopramide—Nervousness—Doxorubicin—urinary bladder cancer	0.000777	0.00149	CcSEcCtD
Metoclopramide—Leukopenia—Epirubicin—urinary bladder cancer	0.000773	0.00148	CcSEcCtD
Metoclopramide—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000769	0.00147	CcSEcCtD
Metoclopramide—Palpitations—Epirubicin—urinary bladder cancer	0.000764	0.00146	CcSEcCtD
Metoclopramide—Confusional state—Methotrexate—urinary bladder cancer	0.00076	0.00146	CcSEcCtD
Metoclopramide—Convulsion—Epirubicin—urinary bladder cancer	0.000749	0.00144	CcSEcCtD
Metoclopramide—Nausea—Etoposide—urinary bladder cancer	0.000747	0.00143	CcSEcCtD
Metoclopramide—Hypertension—Epirubicin—urinary bladder cancer	0.000746	0.00143	CcSEcCtD
Metoclopramide—Agitation—Doxorubicin—urinary bladder cancer	0.000735	0.00141	CcSEcCtD
Metoclopramide—Anxiety—Epirubicin—urinary bladder cancer	0.000733	0.00141	CcSEcCtD
Metoclopramide—Leukopenia—Doxorubicin—urinary bladder cancer	0.000716	0.00137	CcSEcCtD
Metoclopramide—Confusional state—Epirubicin—urinary bladder cancer	0.000711	0.00136	CcSEcCtD
Metoclopramide—Palpitations—Doxorubicin—urinary bladder cancer	0.000707	0.00135	CcSEcCtD
Metoclopramide—Oedema—Epirubicin—urinary bladder cancer	0.000705	0.00135	CcSEcCtD
Metoclopramide—Hypotension—Methotrexate—urinary bladder cancer	0.000704	0.00135	CcSEcCtD
Metoclopramide—Convulsion—Doxorubicin—urinary bladder cancer	0.000693	0.00133	CcSEcCtD
Metoclopramide—Hypertension—Doxorubicin—urinary bladder cancer	0.00069	0.00132	CcSEcCtD
Metoclopramide—Tachycardia—Epirubicin—urinary bladder cancer	0.000688	0.00132	CcSEcCtD
Metoclopramide—Insomnia—Methotrexate—urinary bladder cancer	0.000682	0.00131	CcSEcCtD
Metoclopramide—Anxiety—Doxorubicin—urinary bladder cancer	0.000678	0.0013	CcSEcCtD
Metoclopramide—Dyspnoea—Methotrexate—urinary bladder cancer	0.000672	0.00129	CcSEcCtD
Metoclopramide—Somnolence—Methotrexate—urinary bladder cancer	0.00067	0.00128	CcSEcCtD
Metoclopramide—Hypotension—Epirubicin—urinary bladder cancer	0.000659	0.00126	CcSEcCtD
Metoclopramide—Confusional state—Doxorubicin—urinary bladder cancer	0.000658	0.00126	CcSEcCtD
Metoclopramide—Oedema—Doxorubicin—urinary bladder cancer	0.000652	0.00125	CcSEcCtD
Metoclopramide—Fatigue—Methotrexate—urinary bladder cancer	0.00065	0.00125	CcSEcCtD
Metoclopramide—Insomnia—Epirubicin—urinary bladder cancer	0.000638	0.00122	CcSEcCtD
Metoclopramide—Tachycardia—Doxorubicin—urinary bladder cancer	0.000637	0.00122	CcSEcCtD
Metoclopramide—Dyspnoea—Epirubicin—urinary bladder cancer	0.000629	0.00121	CcSEcCtD
Metoclopramide—Somnolence—Epirubicin—urinary bladder cancer	0.000627	0.0012	CcSEcCtD
Metoclopramide—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000621	0.00119	CcSEcCtD
Metoclopramide—Hypotension—Doxorubicin—urinary bladder cancer	0.00061	0.00117	CcSEcCtD
Metoclopramide—Fatigue—Epirubicin—urinary bladder cancer	0.000608	0.00117	CcSEcCtD
Metoclopramide—Urticaria—Methotrexate—urinary bladder cancer	0.000599	0.00115	CcSEcCtD
Metoclopramide—Body temperature increased—Methotrexate—urinary bladder cancer	0.000596	0.00114	CcSEcCtD
Metoclopramide—Insomnia—Doxorubicin—urinary bladder cancer	0.00059	0.00113	CcSEcCtD
Metoclopramide—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000582	0.00112	CcSEcCtD
Metoclopramide—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000581	0.00111	CcSEcCtD
Metoclopramide—Somnolence—Doxorubicin—urinary bladder cancer	0.00058	0.00111	CcSEcCtD
Metoclopramide—Fatigue—Doxorubicin—urinary bladder cancer	0.000563	0.00108	CcSEcCtD
Metoclopramide—Urticaria—Epirubicin—urinary bladder cancer	0.00056	0.00107	CcSEcCtD
Metoclopramide—Body temperature increased—Epirubicin—urinary bladder cancer	0.000557	0.00107	CcSEcCtD
Metoclopramide—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000555	0.00106	CcSEcCtD
Metoclopramide—Asthenia—Methotrexate—urinary bladder cancer	0.000541	0.00104	CcSEcCtD
Metoclopramide—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000538	0.00103	CcSEcCtD
Metoclopramide—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00052	0.000996	CcSEcCtD
Metoclopramide—Urticaria—Doxorubicin—urinary bladder cancer	0.000518	0.000994	CcSEcCtD
Metoclopramide—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000516	0.000989	CcSEcCtD
Metoclopramide—Diarrhoea—Methotrexate—urinary bladder cancer	0.000516	0.000989	CcSEcCtD
Metoclopramide—Asthenia—Epirubicin—urinary bladder cancer	0.000506	0.00097	CcSEcCtD
Metoclopramide—Dizziness—Methotrexate—urinary bladder cancer	0.000498	0.000956	CcSEcCtD
Metoclopramide—Diarrhoea—Epirubicin—urinary bladder cancer	0.000482	0.000925	CcSEcCtD
Metoclopramide—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000481	0.000922	CcSEcCtD
Metoclopramide—Rash—Methotrexate—urinary bladder cancer	0.000475	0.000911	CcSEcCtD
Metoclopramide—Dermatitis—Methotrexate—urinary bladder cancer	0.000475	0.00091	CcSEcCtD
Metoclopramide—Headache—Methotrexate—urinary bladder cancer	0.000472	0.000905	CcSEcCtD
Metoclopramide—Asthenia—Doxorubicin—urinary bladder cancer	0.000468	0.000898	CcSEcCtD
Metoclopramide—Dizziness—Epirubicin—urinary bladder cancer	0.000466	0.000894	CcSEcCtD
Metoclopramide—Nausea—Methotrexate—urinary bladder cancer	0.000448	0.000858	CcSEcCtD
Metoclopramide—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000446	0.000856	CcSEcCtD
Metoclopramide—Rash—Epirubicin—urinary bladder cancer	0.000445	0.000853	CcSEcCtD
Metoclopramide—Dermatitis—Epirubicin—urinary bladder cancer	0.000444	0.000852	CcSEcCtD
Metoclopramide—Headache—Epirubicin—urinary bladder cancer	0.000442	0.000847	CcSEcCtD
Metoclopramide—Dizziness—Doxorubicin—urinary bladder cancer	0.000431	0.000827	CcSEcCtD
Metoclopramide—Nausea—Epirubicin—urinary bladder cancer	0.000419	0.000803	CcSEcCtD
Metoclopramide—Rash—Doxorubicin—urinary bladder cancer	0.000411	0.000789	CcSEcCtD
Metoclopramide—Dermatitis—Doxorubicin—urinary bladder cancer	0.000411	0.000788	CcSEcCtD
Metoclopramide—Headache—Doxorubicin—urinary bladder cancer	0.000409	0.000784	CcSEcCtD
Metoclopramide—Nausea—Doxorubicin—urinary bladder cancer	0.000388	0.000743	CcSEcCtD
Metoclopramide—CYP11B1—Metabolism—ENO2—urinary bladder cancer	0.000363	0.000759	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000361	0.000755	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000361	0.000755	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—PPARG—urinary bladder cancer	0.00036	0.000753	CbGpPWpGaD
Metoclopramide—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000356	0.000745	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000352	0.000737	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GSTT1—urinary bladder cancer	0.000352	0.000736	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000347	0.000725	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—NQO1—urinary bladder cancer	0.00034	0.00071	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—HPGDS—urinary bladder cancer	0.00034	0.00071	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ENO2—urinary bladder cancer	0.00034	0.00071	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000338	0.000707	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000338	0.000706	CbGpPWpGaD
Metoclopramide—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000332	0.000694	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.00033	0.000689	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GSTT1—urinary bladder cancer	0.00033	0.000689	CbGpPWpGaD
Metoclopramide—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000327	0.000684	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000325	0.000678	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—S100B—urinary bladder cancer	0.000324	0.000677	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000323	0.000675	CbGpPWpGaD
Metoclopramide—DRD3—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.000317	0.000662	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—EP300—urinary bladder cancer	0.000308	0.000643	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—RHOA—urinary bladder cancer	0.000307	0.000642	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000297	0.00062	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—NQO1—urinary bladder cancer	0.000293	0.000612	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—NCOR1—urinary bladder cancer	0.000291	0.000609	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000288	0.000601	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HDAC4—urinary bladder cancer	0.000284	0.000594	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000284	0.000594	CbGpPWpGaD
Metoclopramide—HTR4—GPCR downstream signaling—IL2—urinary bladder cancer	0.000284	0.000593	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—GSTP1—urinary bladder cancer	0.000283	0.000592	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000274	0.000573	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—NQO1—urinary bladder cancer	0.000274	0.000573	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—CXCL8—urinary bladder cancer	0.00027	0.000563	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000266	0.000555	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—TYMS—urinary bladder cancer	0.000264	0.000551	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—GSTM1—urinary bladder cancer	0.000261	0.000544	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—NCOR1—urinary bladder cancer	0.000261	0.000544	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—IL2—urinary bladder cancer	0.000258	0.000538	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TERT—urinary bladder cancer	0.000257	0.000536	CbGpPWpGaD
Metoclopramide—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000252	0.000526	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—EGFR—urinary bladder cancer	0.00025	0.000522	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—GPX1—urinary bladder cancer	0.000249	0.000521	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000248	0.000518	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000247	0.000516	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—ERCC2—urinary bladder cancer	0.000245	0.000512	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GSTP1—urinary bladder cancer	0.000244	0.00051	CbGpPWpGaD
Metoclopramide—DRD2—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.000242	0.000507	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000242	0.000505	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—GLI1—urinary bladder cancer	0.000238	0.000498	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000236	0.000494	CbGpPWpGaD
Metoclopramide—CHRM1—Regulation of Actin Cytoskeleton—KRAS—urinary bladder cancer	0.000236	0.000493	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—EP300—urinary bladder cancer	0.000236	0.000492	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—FGFR3—urinary bladder cancer	0.000236	0.000492	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000232	0.000484	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—EP300—urinary bladder cancer	0.000231	0.000482	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—MTHFR—urinary bladder cancer	0.00023	0.000481	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—ESR1—urinary bladder cancer	0.000229	0.000478	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GSTP1—urinary bladder cancer	0.000229	0.000478	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—TYMS—urinary bladder cancer	0.000227	0.000475	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—NCOR1—urinary bladder cancer	0.000224	0.000469	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GSTM1—urinary bladder cancer	0.000224	0.000469	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	0.000221	0.000463	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000221	0.000462	CbGpPWpGaD
Metoclopramide—DRD3—Circadian rythm related genes—TP53—urinary bladder cancer	0.00022	0.00046	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HDAC4—urinary bladder cancer	0.000217	0.000454	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—GPX1—urinary bladder cancer	0.000215	0.000449	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HDAC4—urinary bladder cancer	0.000213	0.000445	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—TYMS—urinary bladder cancer	0.000212	0.000444	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—ERCC2—urinary bladder cancer	0.000211	0.000441	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—NCOR1—urinary bladder cancer	0.00021	0.000439	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GSTM1—urinary bladder cancer	0.00021	0.000439	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NAT1—urinary bladder cancer	0.00021	0.000438	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	0.00021	0.000438	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—GPX1—urinary bladder cancer	0.000201	0.00042	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CREBBP—urinary bladder cancer	0.000201	0.000419	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—MTHFR—urinary bladder cancer	0.000198	0.000415	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IGF1—urinary bladder cancer	0.000198	0.000414	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—ERCC2—urinary bladder cancer	0.000197	0.000413	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—EGFR—urinary bladder cancer	0.000197	0.000412	CbGpPWpGaD
Metoclopramide—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000193	0.000403	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	0.000192	0.000401	CbGpPWpGaD
Metoclopramide—DRD3—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000192	0.000401	CbGpPWpGaD
Metoclopramide—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000189	0.000394	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PPARG—urinary bladder cancer	0.000187	0.00039	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	0.000186	0.000389	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—KRAS—urinary bladder cancer	0.000186	0.000389	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—MTHFR—urinary bladder cancer	0.000186	0.000388	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—GLI1—urinary bladder cancer	0.000182	0.000381	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—RHOA—urinary bladder cancer	0.000181	0.000379	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—CREBBP—urinary bladder cancer	0.000179	0.000375	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—GLI1—urinary bladder cancer	0.000178	0.000373	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	0.000176	0.000368	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	0.000173	0.000361	CbGpPWpGaD
Metoclopramide—DRD2—Circadian rythm related genes—TP53—urinary bladder cancer	0.000169	0.000352	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—ERBB2—urinary bladder cancer	0.000168	0.000351	CbGpPWpGaD
Metoclopramide—CHRM1—Circadian rythm related genes—TP53—urinary bladder cancer	0.000165	0.000345	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RBX1—urinary bladder cancer	0.000163	0.000341	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	0.000163	0.000341	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PPARG—urinary bladder cancer	0.000161	0.000336	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CXCL8—urinary bladder cancer	0.000159	0.000333	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	0.000159	0.000332	CbGpPWpGaD
Metoclopramide—HTR4—Signaling by GPCR—HRAS—urinary bladder cancer	0.000158	0.000331	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—CREBBP—urinary bladder cancer	0.000155	0.000323	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TSC1—urinary bladder cancer	0.000153	0.000321	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—IL2—urinary bladder cancer	0.000152	0.000318	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PPARG—urinary bladder cancer	0.00015	0.000314	CbGpPWpGaD
Metoclopramide—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	0.00015	0.000313	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CCND1—urinary bladder cancer	0.000148	0.00031	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTGS2—urinary bladder cancer	0.000147	0.000307	CbGpPWpGaD
Metoclopramide—DRD2—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000147	0.000307	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—JAG1—urinary bladder cancer	0.000146	0.000305	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—CREBBP—urinary bladder cancer	0.000145	0.000302	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MMP9—urinary bladder cancer	0.000144	0.000301	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000144	0.0003	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—CDKN1A—urinary bladder cancer	0.000144	0.0003	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—PTEN—urinary bladder cancer	0.000143	0.000299	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—EP300—urinary bladder cancer	0.000137	0.000285	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—SRC—urinary bladder cancer	0.000133	0.000278	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—PTEN—urinary bladder cancer	0.000128	0.000268	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TYMP—urinary bladder cancer	0.000127	0.000266	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTGS2—urinary bladder cancer	0.000127	0.000264	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RBX1—urinary bladder cancer	0.000125	0.000261	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000124	0.000258	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RBX1—urinary bladder cancer	0.000122	0.000255	CbGpPWpGaD
Metoclopramide—CYP11B2—Metabolism—EP300—urinary bladder cancer	0.000122	0.000255	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—MYC—urinary bladder cancer	0.000119	0.000249	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTGS2—urinary bladder cancer	0.000118	0.000247	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—S100B—urinary bladder cancer	0.000118	0.000247	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TSC1—urinary bladder cancer	0.000117	0.000245	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—EGFR—urinary bladder cancer	0.000116	0.000243	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NAT2—urinary bladder cancer	0.000115	0.00024	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TSC1—urinary bladder cancer	0.000115	0.00024	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—RHOA—urinary bladder cancer	0.000112	0.000234	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—JAG1—urinary bladder cancer	0.000112	0.000234	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—PTEN—urinary bladder cancer	0.00011	0.000231	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—KRAS—urinary bladder cancer	0.00011	0.00023	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—JAG1—urinary bladder cancer	0.000109	0.000229	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000108	0.000227	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—NCOR1—urinary bladder cancer	0.000106	0.000222	CbGpPWpGaD
Metoclopramide—CYP11B1—Metabolism—EP300—urinary bladder cancer	0.000105	0.00022	CbGpPWpGaD
Metoclopramide—DRD3—GPCR downstream signaling—IL2—urinary bladder cancer	0.000104	0.000217	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—PTEN—urinary bladder cancer	0.000103	0.000216	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—RRM2—urinary bladder cancer	9.92e-05	0.000207	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—CXCL8—urinary bladder cancer	9.85e-05	0.000206	CbGpPWpGaD
Metoclopramide—CYP17A1—Metabolism—EP300—urinary bladder cancer	9.85e-05	0.000206	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—TP53—urinary bladder cancer	9.77e-05	0.000204	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—RHOA—urinary bladder cancer	9.45e-05	0.000197	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—IL2—urinary bladder cancer	9.41e-05	0.000197	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TERT—urinary bladder cancer	9.38e-05	0.000196	CbGpPWpGaD
Metoclopramide—HTR4—Signaling Pathways—HRAS—urinary bladder cancer	9.35e-05	0.000195	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—RHOA—urinary bladder cancer	9.25e-05	0.000193	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ENO2—urinary bladder cancer	9.19e-05	0.000192	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	9.19e-05	0.000192	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—S100B—urinary bladder cancer	9.05e-05	0.000189	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	8.92e-05	0.000186	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—S100B—urinary bladder cancer	8.86e-05	0.000185	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—FGFR3—urinary bladder cancer	8.6e-05	0.00018	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—RHOA—urinary bladder cancer	8.58e-05	0.000179	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—RHOA—urinary bladder cancer	8.4e-05	0.000176	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ESR1—urinary bladder cancer	8.36e-05	0.000175	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—CXCL8—urinary bladder cancer	8.3e-05	0.000173	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—NCOR1—urinary bladder cancer	8.14e-05	0.00017	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—CXCL8—urinary bladder cancer	8.12e-05	0.00017	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—NCOR1—urinary bladder cancer	7.97e-05	0.000166	CbGpPWpGaD
Metoclopramide—DRD2—GPCR downstream signaling—IL2—urinary bladder cancer	7.93e-05	0.000166	CbGpPWpGaD
Metoclopramide—CHRM1—GPCR downstream signaling—IL2—urinary bladder cancer	7.76e-05	0.000162	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—CXCL8—urinary bladder cancer	7.53e-05	0.000157	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NQO1—urinary bladder cancer	7.41e-05	0.000155	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	7.37e-05	0.000154	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CREBBP—urinary bladder cancer	7.32e-05	0.000153	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IGF1—urinary bladder cancer	7.23e-05	0.000151	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—IL2—urinary bladder cancer	7.2e-05	0.00015	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—EGFR—urinary bladder cancer	7.2e-05	0.00015	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TERT—urinary bladder cancer	7.17e-05	0.00015	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—IL2—urinary bladder cancer	7.05e-05	0.000147	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TERT—urinary bladder cancer	7.02e-05	0.000147	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—KRAS—urinary bladder cancer	6.8e-05	0.000142	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—RHOA—urinary bladder cancer	6.63e-05	0.000138	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—FGFR3—urinary bladder cancer	6.58e-05	0.000138	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—FGFR3—urinary bladder cancer	6.44e-05	0.000135	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ESR1—urinary bladder cancer	6.39e-05	0.000134	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ESR1—urinary bladder cancer	6.26e-05	0.000131	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	6.18e-05	0.000129	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—ERBB2—urinary bladder cancer	6.13e-05	0.000128	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CXCL8—urinary bladder cancer	5.82e-05	0.000122	CbGpPWpGaD
Metoclopramide—DRD3—Signaling by GPCR—HRAS—urinary bladder cancer	5.78e-05	0.000121	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—TYMS—urinary bladder cancer	5.74e-05	0.00012	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	5.68e-05	0.000119	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	5.68e-05	0.000119	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	5.6e-05	0.000117	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—IL2—urinary bladder cancer	5.56e-05	0.000116	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	5.53e-05	0.000116	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	5.51e-05	0.000115	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CREBBP—urinary bladder cancer	5.48e-05	0.000115	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—GPX1—urinary bladder cancer	5.44e-05	0.000114	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CCND1—urinary bladder cancer	5.42e-05	0.000113	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IGF1—urinary bladder cancer	5.42e-05	0.000113	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—EGFR—urinary bladder cancer	5.39e-05	0.000113	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	5.34e-05	0.000112	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MMP9—urinary bladder cancer	5.26e-05	0.00011	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—CDKN1A—urinary bladder cancer	5.24e-05	0.00011	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—PTEN—urinary bladder cancer	5.23e-05	0.000109	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	5.2e-05	0.000109	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—KRAS—urinary bladder cancer	5.09e-05	0.000106	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	5.07e-05	0.000106	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	5.02e-05	0.000105	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EP300—urinary bladder cancer	4.99e-05	0.000104	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—RHOA—urinary bladder cancer	4.96e-05	0.000104	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—SRC—urinary bladder cancer	4.85e-05	0.000101	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	4.69e-05	9.81e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—ERBB2—urinary bladder cancer	4.59e-05	9.6e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	4.45e-05	9.3e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	4.42e-05	9.24e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CXCL8—urinary bladder cancer	4.36e-05	9.1e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—MYC—urinary bladder cancer	4.35e-05	9.08e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling by GPCR—HRAS—urinary bladder cancer	4.33e-05	9.04e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—IL2—urinary bladder cancer	4.25e-05	8.89e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—EGFR—urinary bladder cancer	4.25e-05	8.88e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—IL2—urinary bladder cancer	4.16e-05	8.7e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	4.15e-05	8.66e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PPARG—urinary bladder cancer	4.07e-05	8.5e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CCND1—urinary bladder cancer	4.06e-05	8.48e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	4.03e-05	8.41e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—KRAS—urinary bladder cancer	4.02e-05	8.39e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	4.01e-05	8.38e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	4e-05	8.36e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MMP9—urinary bladder cancer	3.94e-05	8.23e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	3.93e-05	8.2e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—PTEN—urinary bladder cancer	3.92e-05	8.18e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	3.91e-05	8.17e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EP300—urinary bladder cancer	3.82e-05	7.98e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EP300—urinary bladder cancer	3.74e-05	7.81e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—SRC—urinary bladder cancer	3.71e-05	7.76e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—SRC—urinary bladder cancer	3.63e-05	7.59e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—TP53—urinary bladder cancer	3.57e-05	7.46e-05	CbGpPWpGaD
Metoclopramide—DRD3—Signaling Pathways—HRAS—urinary bladder cancer	3.41e-05	7.13e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—MYC—urinary bladder cancer	3.33e-05	6.95e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—MYC—urinary bladder cancer	3.25e-05	6.8e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	3.25e-05	6.8e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	3.2e-05	6.69e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—EGFR—urinary bladder cancer	3.18e-05	6.65e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	3.07e-05	6.42e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—KRAS—urinary bladder cancer	3.01e-05	6.28e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.79e-05	5.83e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—TP53—urinary bladder cancer	2.73e-05	5.71e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—TP53—urinary bladder cancer	2.67e-05	5.59e-05	CbGpPWpGaD
Metoclopramide—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.66e-05	5.56e-05	CbGpPWpGaD
Metoclopramide—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	2.61e-05	5.46e-05	CbGpPWpGaD
Metoclopramide—CHRM1—Signaling Pathways—HRAS—urinary bladder cancer	2.56e-05	5.34e-05	CbGpPWpGaD
